MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC cut its holdings in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 9.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 105,473 shares of the company’s stock after selling 10,830 shares during the quarter. Los Angeles Capital Management LLC owned 0.16% of MeiraGTx worth $444,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new position in MeiraGTx during the 1st quarter worth $25,000. China Universal Asset Management Co. Ltd. raised its holdings in MeiraGTx by 66.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 12,246 shares of the company’s stock valued at $74,000 after acquiring an additional 4,892 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in MeiraGTx in the first quarter worth approximately $100,000. BNP Paribas Financial Markets grew its holdings in MeiraGTx by 73.9% during the 1st quarter. BNP Paribas Financial Markets now owns 19,242 shares of the company’s stock worth $117,000 after acquiring an additional 8,178 shares in the last quarter. Finally, Panagora Asset Management Inc. purchased a new stake in shares of MeiraGTx in the 2nd quarter valued at approximately $97,000. Hedge funds and other institutional investors own 67.48% of the company’s stock.

Insider Buying and Selling

In other news, Director Perceptive Advisors Llc acquired 1,250,000 shares of MeiraGTx stock in a transaction on Monday, August 12th. The stock was bought at an average price of $4.00 per share, for a total transaction of $5,000,000.00. Following the completion of the purchase, the director now owns 12,531,103 shares in the company, valued at $50,124,412. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 8.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

MGTX has been the subject of several recent analyst reports. Royal Bank of Canada decreased their price objective on shares of MeiraGTx from $11.00 to $9.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Chardan Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of MeiraGTx in a research report on Wednesday, July 31st.

MeiraGTx Stock Up 1.9 %

MGTX stock opened at $4.25 on Friday. The company’s 50 day moving average is $4.37 and its two-hundred day moving average is $4.96. MeiraGTx Holdings plc has a twelve month low of $3.49 and a twelve month high of $7.60. The company has a current ratio of 2.36, a quick ratio of 2.36 and a debt-to-equity ratio of 1.04. The stock has a market cap of $273.30 million, a P/E ratio of -3.63 and a beta of 1.28.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.45). MeiraGTx had a negative net margin of 1,146.81% and a negative return on equity of 152.82%. The company had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $16.38 million. Research analysts expect that MeiraGTx Holdings plc will post -1.37 earnings per share for the current fiscal year.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.